Emory School of Medicine
Chief of Medical Oncology
Department of Hematology & Medical Oncology
Dr. Suresh Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, where he also served as a Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association of Lung Cancer Study. Dr. Ramalingam plays an active role in the Eastern Cooperative Oncology Group as the Co-Chair of the Thoracic Malignancies Sub-committee. He also serves on the editorial board of leading cancer journals such as Journal of Clinical Oncology, Cancer, Clinical Lung Cancer and Cancer, Chemotherapy and Pharmacology. Dr. Ramalingam is the recipient of several awards, including the ‘James Eckman Award for Excellence in Teaching’, Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is also a recipient of the ‘ASCO Career Development Award’ (2006-09). Dr. Ramalingam serves on several international, national and Institutional Committees. He is currently a recipient of peer-reviewed grants from the National Cancer Institute, Department of Defense, and Georgia Cancer Coalition.
Dr. Ramalingam’s research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies to patients. Dr. Ramalingam has conducted several early phase clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. His research work has been published in leading journals such as the Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer. He is currently involved in the development of agents that inhibit the mTOR, HDAC, DNA repair and EGFR pathways.
View publications on PubMed
View clinical trials at Winship Cancer Institute